Sylvant
Active Ingredient(s): SiltuximabFDA Approved: * April 22, 2014
Pharm Company: * JANSSEN BIOTECH
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Sylvant Overview
Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6.[1][2] Siltuximab has been investigated for the treatment of neoplastic diseases:[3] metastatic renal cell cancer,[4] prostate cancer,[5] and Castleman's disease,[6][7] among ot...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Siltuximab
Recent Sylvant Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Siltuximab
- Injection: 100mg, 400mg
NDC Database Records for Sylvant: (4 results)
Sorted by National Drug Code- 57894-420 Sylvant 100 mg Intravenous Injection, Powder, Lyophilized, for Solution by Janssen Biotech, Inc.
- 57894-421 Sylvant 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by Janssen Biotech, Inc.
- 73090-420 Sylvant 100 mg Intravenous Injection, Powder, for Solution by Eusa Pharma (Uk) Ltd
- 73090-421 Sylvant 400 mg Intravenous Injection, Powder, for Solution by Eusa Pharma (Uk) Ltd